Business
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer'
About this update from Anavex Life Sciences Corp.
[{"type":"image","alt":"Anavex Life Sciences Corp.","displaySize":"","headline":null,"caption":"Anavex Life Sciences Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/c04acbca5a62a2d4b04d7751547db9de"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/F5ZrlIN03cn8vEBULiAt0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c04acbca5a62a2d4b04d7751547db9de","width":300,"height":61}},"lazy":false},{"type":"text","content":"New data show that blarcamesine completely rescued impaired motor function","length":74,"tagName":"p"},{"type":"text","content":"Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine","length":116,"tagName":"p"},{"type":"text","content":"New Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration","length":90,"tagName":"p"},{"type":"text","content":"NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new data of blarcamesine in a new Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration. Significant treatment effects of blarcamesine were detected using both a test of impaired motor function and a biomarker of dopaminergic nerve fiber density, indicating fiber regrowth in striatum after 6 weeks of blarcamesine treatment. Results were presented at the AD/PD™ 2026 Conference.","length":838,"tagName":"p"},{"type":"text","content":"The model addresses both alpha-synuclein accumulation (protein buildup) and noradrenergic degeneration, a combination of lesions that mimics key aspects of Parkinson's disease pathology. The study, presented at the AD/PD™ 2026 Conference, examines whether modulating these interconnected disease pathways with blarcamesine can actively counteract and reverse Parkinson’s disease progression.","length":400,"tagName":"p"},{"type":"text","content":"“These new findings are highly e...